简体中文
|
English
HOME
ABOUT US
Introduction
Company Culture
Management Team
RESEARCH CENTER
Product Pipelines
ADC Technology
NEWS AND MEDIA
CAREERS
CONTACT US
HOME
ABOUT US
RESEARCH CENTER
NEWS AND MEDIA
CAREERS
CONTACT US
NEWS AND MEDIA
Home
NEWS AND MEDIA
MRG002 completed an IND application in the United States on April 10, 2020 and approved by the US FDA for a phase I/II clinical study of HER2-positive gastric/gastroesophageal and pharyngeal junction cancer on May 11, 2020.
Release time:2020-05-11